Accessibility Menu
Caribou Biosciences Stock Quote

Caribou Biosciences (NASDAQ: CRBU)

$2.53
(-10.9%)
-0.31
Price as of October 22, 2025, 3:58 p.m. ET

KEY DATA POINTS

Current Price
$2.53
Daily Change
(-10.9%) $0.31
Day's Range
$2.44 - $2.85
Previous Close
$2.53
Open
$2.83
Beta
0
Volume
1,420,687
Average Volume
1,212,128
Market Cap
264.5M
Market Cap / Employee
$2.84M
52wk Range
$0.66 - $3
Revenue
-
Gross Margin
0.49%
Dividend Yield
N/A
EPS
-$1.79
CAPs Rating
-
Industry
Biotechnology

The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More

Caribou Biosciences Return vs. S&P

1 Year5 Year5 Year AnnualizedSince IPO
CRBU+44.16%N/AN/A-83%
S&P+15.06%+95.03%+14.29%+53%

Caribou Biosciences Company Info

Caribou Biosciences, Inc. engages in the development of an internal pipeline of off-the-shelf CAR-T and CAR-NK cell therapies. Its tools and technologies provide transformative capabilities to basic and applied biological research, therapeutic development, agricultural biotechnology, and industrial biotechnology. The company was founded by Jennifer A. Doudna, Rachel E. Haurwitz, Martin Jinek and James Berger on October 28, 2011 and is headquartered in Berkeley, CA.

News & Analysis

Financial Health

General

Q2 2025YOY Change
Revenue$2.67M-23.0%
Gross Profit$1.50M-42.5%
Gross Margin56.24%-19.0%
Market Cap$117.19M-20.9%
Market Cap / Employee$0.80M0.0%
Employees147-7.0%
Net Income-$54.10M-43.5%
EBITDA-$34.26M19.7%

Currently no data to display

Revenue Growth Rate

Currently no data to display.

Earnings Per Share Growth Rate

Currently no data to display.

Assets

Q2 2025YOY Change
Net Cash$25.20M-33.4%
Accounts Receivable$0.82M-30.6%
Inventory00.0%

Liabilities

Q2 2025YOY Change
Long Term Debt$23.56M-7.7%
Short Term Debt$2.29M27.0%

Ratios

Q2 2025YOY Change
Return On Assets-55.32%-21.2%
Return On Invested Capital-61.90%-1.1%

Cash Flow

Q2 2025YOY Change
Free Cash Flow-$28.68M18.3%
Operating Free Cash Flow-$28.26M14.0%

Valuation

MetricQ3 2024Q4 2024Q1 2025Q2 2025YoY Change
Price to Book0.630.510.330.5425.03%
Price to Sales15.4514.508.5312.85187.22%
Price to Tangible Book Value0.630.510.330.5425.03%
Enterprise Value to EBITDA0.651.012.341.19-40.94%
Return on Equity-43.6%-48.0%-52.8%-68.9%61.92%
Total Debt$26.66M$26.51M$26.22M$25.85M-5.41%

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.